A Multi-center Phase Ib/II Trial of Nivolumab/Ipilimumab-Primed Immunotransplant for Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients.
Phase of Trial: Phase I/II
Latest Information Update: 30 May 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 06 Mar 2018 Status changed from not yet recruiting to recruiting.
- 15 Dec 2017 Planned initiation date changed from 1 Dec 2017 to 1 Feb 2018.
- 12 Oct 2017 New trial record